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SUMMARY 
Alkaptonuria (AKU) is an ultra-rare autosomal recessive disorder resulting from a deficiency 
of homogentisate 1,2 dioxygenase (HGD), an enzyme involved in the catabolism of 
phenylalanine and tyrosine. Loss of HGD function prevents metabolism of homogentisic acid 
(HGA) leading to increased levels of plasma HGA and urinary excretion. Excess HGA becomes 
deposited in collagenous tissues and subsequently undergoes polymerization, principally in 
the cartilages of loaded joints, in a process known as ochronosis. This results in an early 
onset, devastating osteoarthropathy for which there is currently no effective treatment. We 
recently described the natural history of ochronosis in a murine model of AKU, 
demonstrating that deposition of ochronotic pigment begins very early in life and 
accumulates with age. Using this model we were able to show that lifetime treatment with 
nitisinone, a potential therapy for AKU, was able to completely prevent deposition of 
pigment. However, although nitisinone has been shown to inhibit ochronotic deposition, 
whether it can also facilitate removal of existing pigment has not yet been examined. We 
describe here that mid-life administration of nitisinone to AKU mice arrests further 
deposition of ochronotic pigment in the tibio-femoral joint, but does not result in the 
clearance of existing pigment. We also demonstrate the dose-dependent response of 
plasma HGA to nitisinone, highlighting its efficacy for personalised medicine, where dosage 
can be tailored to the individual AKU patient.  
 
SYNOPSIS 
Nitisinone arrests further deposition of ochronotic pigment when administered mid-life, it 
does not reduce existing pigmentation, and it reduces the plasma HGA levels in a dose-
dependent manner. 
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INTRODUCTION 
Alkaptonuria (AKU) has a unique place in the history of metabolic disease as the first 
disorder to be described as an ‘inborn error of metabolism’ by the distinguished English 
physician, Sir Archibald Garrod (Garrod 1902). AKU is an ultra-rare autosomal recessive 
disorder with a worldwide incidence of between 1 in 250,000-1,000,000 live births 
(Phornphutkul et al 2002). AKU results from mutations in homogentisate 1,2-dioxygenase 
(HGD) (EC 1.13.11.5), the enzyme involved in the catabolism of phenylalanine and tyrosine 
(La Du et al 1958). Loss of HGD function results in both increased plasma levels of 
homogentisic acid (HGA), and HGA excretion. Urinary HGA darkens on exposure to air, and 
is typically observed as the first symptom in patients who present with AKU. Elevated levels 
of plasma HGA ultimately leads to the pigmentation of cartilaginous tissues, following the 
deposition and subsequent polymerisation of HGA in a process known as ochronosis. This 
results in an early-onset, devastating osteoarthropathy for which there is currently no 
effective treatment. 
Nitisinone (2-(2-nitro-4-(trifluoromethyl) benzoyl) cyclohexane-1,3-dione) is a reversible 
inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (EC 1.13.11.27), the enzyme 
responsible for producing HGA. Originally developed as a herbicide (Schulz et al 1993), it is 
routinely used for the treatment of hereditary tyrosinaemia type 1 (McKiernan 2006). 
Nitisinone is viewed as a potential treatment for AKU as it prevents accumulation of HGA in 
plasma. Ochronosis has recently been described in two murine models of AKU (Taylor et al 
2012, Preston et al 2014). In the latter of the two models, we have described the efficacy of 
nitisinone in treating ochronosis in a murine model of AKU and demonstrated that lifetime 
administration of nitisinone reduced plasma HGA by 88% and prevented ochronotic pigment 
deposition in the tibio-femoral joint (Preston et al 2014). This was the first time that 
inhibition of ochronosis by nitisinone had been demonstrated, and highlighted the efficacy 
of nitisinone as a treatment for AKU.  
As a large proportion of AKU patients already suffer from osteoarthropathy, it is important 
to determine if nitisinone’s efficacy is purely prophylactic, or whether it can facilitate repair 
and regeneration of damaged cartilage during natural metabolic turnover. Although 
pigmentation in AKU mice can be prevented throughout their lifetime by administration of 
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nitisinone, there is no data on whether ochronosis is reversible. Here we describe that the 
mid-life administration of nitisinone to AKU mice successfully arrests further deposition of 
ochronotic pigment in the tibio-femoral joint, but does not result in the reduction of existing 
pigment. We also demonstrate that the response of plasma HGA to nitisinone treatment is 
dose-dependent, which should facilitate tailored treatment of AKU patients presenting with 
differing degrees of severity. 
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MATERIALS AND METHODS 
Mice 
Hgd-/- (AKU) mice on a BALB/c or C57BL/6 background were used for all experiments. All 
mice were housed and maintained within the University of Liverpool’s Biological Services 
Unit (BSU) in accordance with Home Office UK guidelines.  
Sample preparation 
Tail bleed samples were collected into microvettes (Sarstedt, CB 300) and stored at 4°C prior 
to processing within 2hrs, using an adaptation of the Bory method (Bory et al 1990). Briefly, 
whole blood was centrifuged at 1500×g for 10 min at 4°C, and the plasma deproteinised by 
adding 5.8 M perchloric acid (Sigma, UK) equivalent to 10% of the plasma and containing 0.1 
mM 4-amino-2-chlorobenzoic acid (Sigma, UK) as internal standard. Acidified supernatant 
was stored at −20°C. A 150µl tail-bleed volume yielded approximately 25µl of deproteinised 
plasma.  
Chromatographic conditions 
Plasma HGA concentration was determined via HPLC as described previously (Preston et al 
2014), on a Phenomenex Kinetex XB-C18 column, 2.6µ (4.6 x100mm). Briefly, the initial 
mobile phase was 100% buffer A (12mM orthophosphoric acid, Sigma, UK), before 
increasing buffer B (100% methanol, Sigma, UK) from 0-80% over 10mins. Detection was by 
UV at 290nm.  
Mid-life nitisinone treatment 
A cohort of eight BALB/c Hgd-/- mice (four male, four female) were provided with filtered 
water from 8 to 34 weeks of age. They were then provided with an ad libitum supply of 
water containing 4mg/l of nitisinone (Shanghai Elittes Organics, China) from 34 to 79 weeks 
of age. The control group of 8 BALB/c Hgd-/- mice (four male, four female) were untreated 
over the same time period. Plasma was taken at 35 weeks, and then sampled regularly by 
tail bleed over the mouse lifetime. Tibio-femoral joints were taken for histological analysis 
at end of study. Analysis of joint pigmentation was also performed at different ages, in 
either BALB/c Hgd-/- or C57BL/6 Hgd-/- mice to build up a disease progression timeline. 
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Nitisinone dose-response    
Six cohorts of four age-matched C57BL/6 Hgd-/- mice (two male, two female) had their 
plasma sampled at 54 weeks, and then immediately treated with an ad libitum supply of 
water containing either 4mg/L, 1mg/L, 0.5mg/L, 0.25mg/L, 0.125mg/L, or 0mg/L of 
nitisinone for 13 days. Plasma was sampled again 7 and 19 days post treatment, and its HGA 
concentration determined by HPLC. 
Histological analysis 
Mice were euthanised with Pentoject (sodium pentobarbitone 20% w/v) and their tibio-
femoral joint harvested and stored in 10% phosphate buffered formalin solution, pH 7.4, for 
a minimum of 24hrs. Tissues were washed in phosphate buffered saline before 
decalcification in 12% EDTA for 7 days. Tibio-femoral joints were dissected free of excess 
muscle then paraffin embedded in the coronal plane to enable simultaneous evaluation of 
both the medial and lateral compartments of the joint, as recommended by the 
Osteoarthritis Research Society International (OARSI) histopathology initiative. The first 
section that encompassed both the tibial plateau and femoral condyles was selected as 
representative of each mouse. Sections were mounted on glass slides, rehydrated and 
stained with H&E or Schmorl’s stain, previously shown to be a sensitive method for the 
detection of ochronotic pigment (Tinti, Taylor et al. 2011). Sections were dehydrated 
through graded alcohols, and mounted with DPX resin (VWR International, UK) for 
examination by light microscopy. 
Quantification of pigmented chondrons 
The first whole section that encompassed the entire tibio-femoral joint (MTP, MFC, LTP, & 
LFC) was selected as representative of each mouse for quantification analysis. From these 
sections, pigmented chondrons present in the articular cartilage and entheses of the 
femoral condyles and articular cartilage of the tibial plateau were quantified. 
Statistical analyses 
Comparisons in pigmentation rates between treated and untreated groups were performed 
using an independent samples t-test. Descriptive statistics are reported as mean and 
standard deviation (SD) as normality was achieved, while results were considered as 
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statistically significant at the 5% level. Data analysis was undertaken using Stata 13 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.).  
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RESULTS 
Mid-life treatment with 4mg/L nitisinone from 35-79 weeks of age suppressed plasma HGA 
concentration by approximately fifteen fold, in agreement with previous work (Preston et al 
2014) (Fig. 1). The reduction in plasma HGA following 44 weeks of nitisinone treatment, 
translated into a statistically significant difference (t=4.645, p=0.001) in the mean number of 
pigmented chondrons visible in the nitisinone treated mice at 79 weeks, equal to 88 
(SD=26.5) (Fig. 2b), relative to aged-matched untreated AKU mice, equal to 201.2 (SD=48.4) 
(Fig. 3). The degree of pigmentation observed in nitisinone treated BALB/c Hgd-/- mice at 79 
weeks was considered equivalent to that observed in untreated 34 week old BALB/c Hgd-/- 
mice (Fig. 2a), correspondent with the time at which treatment began. This demonstrated 
that mid-life treatment with nitisinone arrested further deposition of ochronotic pigment 
but did not clear previously laid-down pigment, resulting in higher observable chondron 
pigmentation than AKU mice treated from birth (Fig. 2d). The number of pigmented 
chondrons observed in the untreated mice at 79 weeks (Fig. 2c) was consistent with levels 
previously reported in the natural history study of BALB/c Hgd-/- mice (Preston et al 2014).  
Quantification of pigmented chondrons over time (Fig. 3) confirmed that although the 
degree of deposition between AKU mice was highly variable (even within highly inbred 
mouse strains); progressive accumulation of ochronotic pigment was consistent with ageing. 
Nevertheless, mid-life treatment with nitisinone effectively inhibited further deposition of 
ochronotic pigment.     
Plasma HGA concentration was also highly variable in AKU mice, but was observed to 
respond in a highly dose-dependent fashion to nitisinone treatment, when plotted as a 
percentage of its pre-treatment value (Fig. 4). Higher concentrations of nitisinone resulted 
in greater suppression of plasma HGA variability within cohorts, while removal of nitisinone 
after 13 days resulted in a rebound of plasma HGA levels.  
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DISCUSSION 
We have previously shown that nitisinone treatment from birth can prevent ochronosis in 
the adult AKU mouse (Preston et al 2014). Here we demonstrate that beginning nitisinone 
treatment mid-way through life (34 weeks) is sufficient to arrest further disease 
progression. Remarkably, 45 weeks after treatment, the mean number of pigmented 
chondrons observed within the knee joint was no greater than that typical of untreated 34 
week old AKU mice, according to our disease progression timeline (Fig. 3). Unlike in mice 
treated with nitisinone from birth however (Fig. 2d), pigmentation could still be observed 
and quantified. It is evident therefore, that while nitisinone can prevent further deposition 
of ochronotic pigment, it does not reduce pre-existing pigmentation by enabling 
turnover/replacement of damaged cartilage. This strongly implies that in order to minimise 
the irreparable joint damage typical of AKU disease progression in humans, treatment with 
nitisinone should begin as early as possible. Although there was no evidence that mid-life 
treatment with nitisinone could facilitate removal of existing pigmentation, it did arrest any 
further deposition of ochronotic pigment which may lead to the prevention or slowing down 
of disease progression in patients with established ochronosis. 
Establishing a minimum effective nitisinone dose is fundamental to reducing the cost of 
lifetime treatment and minimising potential side effects such as corneal keratopathy 
(Introne et al 2011). As plasma HGA concentration in AKU patients is highly variable, we 
therefore examined dose–response sensitivity to nitisinone to determine the practicality of 
tailoring nitisinone treatment dose to the patient. A clear dose-response effect was 
observed between nitisinone and plasma HGA levels, which decreased consistently 
following increased doses of nitisinone. Treatment with 4mg/L nitisinone reduced plasma 
HGA by 90% over a 13-day period when compared with baseline controls. Ranganath and 
colleagues recently showed a similar dose-response effect of nitisinone when analysing 
urinary HGA excretion over a 24h period in AKU patients (Ranganath et al 2014). Both our 
data and that of Ranganath et al highlight the efficacy of nitisinone in reducing the levels of 
circulating HGA. As excellent dose-response sensitivity was observed between differing 
nitisinone concentrations and plasma HGA levels, it may be possible to tailor individual 
treatment plans for AKU patients. 
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In summary we have shown that nitisinone can effectively inhibit ochronotic deposition in 
an alkaptonuric mouse model, and if introduced mid-life can arrest any further disease 
progression. Nitisinone treatment does not result in the removal of existing ochronotic 
pigmentation, and cannot therefore be used to treat existing joint damage. Plasma HGA 
concentrations display excellent sensitivity to treatment dose, facilitating the tailoring of 
therapy to patient disease severity. 
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Fig. 1 The effect of mid-life (34 weeks) dietary supplementation with 4mg/L nitisinone 
on the plasma HGA concentration in AKU mice.   
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Fig. 2 a Photomicrograph displaying pigmented chondrons (arrows) in a 35 week 
old BALB/c Hgd-/- mouse, prior to treatment with nitisinone. b Administration of 
nitisinone (4mg/l) at 35 weeks prevented large scale pigmentation of chondrons 
in the tibio-femoral joint. The number of pigmented chondrons (arrows) observed 
in the nitisinone treated BALB/c Hgd-/- mice at 80 weeks was comparable to 
those seen in untreated BALB/c Hgd-/- mice at 35 weeks (Fig.1, 2a). c 
Photomicrograph of an 80 week old untreated BALB/c Hgd-/- mouse. Large 
numbers of pigmented chondrons (arrows) were present throughout the tibio-
femoral joint, highlighting the effectiveness of nitisinone when given mid-life (Fig. 
2b). d Lifetime treatment with nitisinone (4mg/l) prevented any deposition of 
ochronotic pigment in the tibio-femoral joint. All images were taken from the 
lateral femoral condyle of BALB/c Hgd-/- mice. Bar = 20μm.   
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Fig. 3 Quantification of pigmented chondrons in the tibio-femoral joint of AKU mice, 
depicting ochronotic pigment deposition over time, and the effect of treatment with 4mg/L 
nitisinone when administered mid-life. Treatment at 34 weeks prevented further deposition 
of ochronotic pigment by week 79, but did not reverse the effects of previously laid down 
pigment. Quantification of pigmented chondrons was performed on a single section from 
each mouse, and does not represent the total cell number in each mouse. 
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Fig. 4 The dose response to nitisinone (as percentage change of plasma HGA concentration) 
in AKU mice, and recovery. 
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